文献速递浆细胞疾病

首创RNA降解剂在临床前模型中降低c-MYC表达并抑制骨髓瘤细胞存活

A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models.
PubMed 文献 · Blood · 2026-07-29

本研究评估了一种靶向MYC mRNA的RiboTAC(MYC-RiboTAC)在原发性多发性骨髓瘤(MM)患者样本和MM细胞系中的生物学活性与分子机制。MYC-RiboTAC以RNase L依赖方式降低MYC mRNA和蛋白水平,选择性抑制MYC驱动的转录程序,在存在骨髓保护下仍抑制MM细胞生长,并与卡非佐米、来那度胺和泊马度胺协同。小鼠中安全性和药代动力学良好,在两个MM异种移植模型中显著抑制肿瘤生长。

要点

  • MYC-RiboTAC以RNase L依赖方式降解MYC mRNA并降低蛋白水平。
  • 在MM细胞中抑制生长,与卡非佐米、来那度胺、泊马度胺协同。
  • 小鼠中安全性及药代动力学良好,两个异种移植模型显著抑瘤。

核心结论

  • RNA降解剂可靶向编码MYC等「不可成药」蛋白的mRNA,为精准癌症治疗提供潜在途径。

研究设计与样本

  • 在原发性MM患者样本和MM细胞系中评估MYC-RiboTAC的生物学活性与分子机制。
  • MYC-RiboTAC为异双功能分子,由靶向MYC内部核糖体进入位点(IRES)的小分子与招募内源性RNase L的小分子偶联而成。
  • 在小鼠中评估安全性和药代动力学,并在两个NOD SCID小鼠MM异种移植模型中评估肿瘤生长。

主要发现

  • MYC-RiboTAC以RNase L依赖方式降低MYC mRNA和蛋白水平。
  • 选择性抑制MYC驱动的转录程序,并对MM exhibit强效抗MM活性。
  • 在共表达MYC和RNase L的MM细胞中有效抑制细胞生长,即使存在保护性骨髓。
  • 与卡非佐米、来那度胺和泊马度胺等临床活性药物协同。
  • 小鼠中显示良好安全性和药代动力学特征,并在两个MM异种移植模型中显著抑制肿瘤生长。

临床怎么用

  • 临床前数据支持进一步开发MYC-RiboTAC作为靶向MYC的MM治疗策略。
  • 与卡非佐米、来那度胺和泊马度胺的协同作用提示联合治疗潜力。

局限性

  • 研究为临床前评估,尚未在人体中验证疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The c-MYC (MYC) oncogene is a critical driver of multiple myeloma (MM), however, direct targeting of the MYC protein has proven challenging due to its intrinsic structural disorder. In this study, we evaluated the biological activity and molecular mechanism of a ribonuclease-targeting chimera (RiboTAC) designed to promote the degradation of MYC mRNA (MYC-RiboTAC) across a panel of primary patient MM samples and MM cell lines. This heterobifunctional molecule consists of a small molecule targeting the MYC internal ribosomal entry site (IRES) conjugated to a small-molecule recruiter of endogenous RNaseL. The MYC-RiboTAC reduces MYC mRNA and protein levels in an RNase L-dependent manner, selectively inhibits MYC-driven transcriptional programs, and exhibits potent anti-MM activity. It effectively suppresses cell growth in MM cells co-expressing MYC and RNase L, even in the presence of the protective bone marrow. Furthermore, it synergizes with clinically active agents such as carfilzomib, lenalidomide, and pomalidomide. Importantly, MYC-RiboTAC displays favorable safety and pharmacokinetic profiles in mice and significantly suppresses tumor growth in NOD SCID mice bearing MM xenografts, as shown in two different models. These findings highlight the potential of RNA degraders to target mRNAs encoding "undruggable" proteins such as MYC, offering a promising avenue for precision cancer therapy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Maisano D, Wang T, Kulp SB, et al. A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models. Blood. 2026. PMID: 42526890. doi:10.1182/blood.2026033241

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。